In a phase 3 clinical trial, tenapanor significantly lowered elevated blood phosphate in patients receiving maintenance hemodialysis, resulting in an average reduction of 1.0–1.2 mg/dL over 8 weeks.

Side effects were largely limited to softening of stool and more frequent bowel movements.